{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:40:04Z","timestamp":1747845604711,"version":"3.41.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Princ Pract"],"abstract":"<jats:p>Objectives:  The overexpression of plasminogen activator inhibitor-1 (PAI-1) was frequently observed during COVID-19, and it was found to be closely associated with disease severity. We have analyzed the PAI-1 status in fully recovered post-COVID patients. \nSubjects and Methods: In a case-control and cross-sectional study, we compared 377 patients, 30-210 days after PCR-verified COVID-19 and 884 COVID-naive controls.  Results: Post-COVID patients (\"cases\") showed significantly higher plasma PAI-1 concentrations than COVID-naive controls. This difference remained significant even after complex adjustment by multiple regression. On the other hand, since the strongest covariate of increased PAI-1 was antihypertensive treatment, the difference between cases and controls in those who were on antihypertensives completely disappeared. In the subgroup of post-COVID patients only, we also found that highly symptomatic patients or those who required hospitalization in the acute phase showed significantly higher PAI-1 than patients with only mild symptoms of the disease. Similarly, the presence of \u03b2 mutation increased the relative risk (\u224811 times) of high post-COVID concentrations of PAI-1.  Similarly, the presence of \uf062 mutation increased the relative risk (\u224811 times) of high post-COVID concentrations of PAI-1. Conclusions: Increased values of PAI-1 can persist for several months after complete recovery from COVID-19 (namely by \uf062\uf020variant of the virus), and their expression also corresponded to clinical course of the disease.\n\u2003\n<\/jats:p>","DOI":"10.1159\/000546399","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:01:11Z","timestamp":1747843271000},"page":"1-20","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Expression of Plasminogen Activator Inhibitor-1 in Patients Recovered From COVID-19 Disease"],"prefix":"10.1159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-3749","authenticated-orcid":false,"given":"Otto","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"B\u00edlkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Nezbedov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Karnosov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindra","family":"Windrichov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Hirmerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Pazdiora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Filipovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,5,21]]},"container-title":["Medical Principles and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T16:01:11Z","timestamp":1747843271000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000546399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000546399","archive":["Portico"],"relation":{},"ISSN":["1011-7571","1423-0151"],"issn-type":[{"value":"1011-7571","type":"print"},{"value":"1423-0151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}